Caris Life Sciences Validates AI-Enabled Blood-Based Cancer Assay

Caris Life Sciences has announced a landmark study validating the Caris Assure blood-based assay for multi-cancer early detection, minimal residual disease, and therapy selection, announced in a press release. The study, published in Scientific Reports, highlights the assay's diagnostic, prognostic, and predictive capabilities.

The Caris Assure platform integrates Whole Exome Sequencing and Whole Transcriptome Sequencing with advanced machine learning, offering comprehensive molecular profiling of over 23,000 genes in plasma. This approach sets a new standard for blood-based testing, enabling accurate early detection and sensitive disease monitoring without the need for prior tissue biopsies.

The study demonstrated the assay's effectiveness in multi-cancer early detection with sensitivities ranging from 83.1% to 95.7% across cancer stages I-IV, and a specificity of 99.6%. Additionally, the assay showed significant predictive power for recurrence monitoring, with hazard ratios of 33.4 for minimal residual disease and 4.39 for therapeutic monitoring.

Caris Life Sciences is actively pursuing regulatory and reimbursement pathways to expand the assay's applications beyond therapy selection in advanced cancers, aiming to enhance cancer care management through this innovative platform.